ASCO 2023 | BIOMEDE: comparing 3 targeted therapies + radiotherapy from ITCC, SIOPE-Brain and ANZCHOG

Jacques Grill, MD, PhD, Gustave Roussy Cancer Institute, Villejuif, France, discusses a the Phase II BIOMEDE (NCT02233049) randomized biomarker-driven platform trial conducted to compare three targeted therapies (erlotinib, everolimus, and dasatinib) in combination with radiotherapy in newly diagnosed patients with diffuse intrinsic pontine glioma (DIPG), a highly aggressive brain cancer in children. A total of 233 patients with confirmed DIPG were enrolled in the trial, and their tumors underwent genetic analysis to identify prognostic and theranostic biomarkers. The primary endpoint of overall survival (OS) was evaluated. The study found that the addition of targeted therapies to radiotherapy did not significantly improve OS compared to historical data. The molecular profiling of tumors revealed the impact of copy number aberrations (CNA) on survival, with a subgroup of tumors characterized by TP53 mutations and more CNA associated with poor prognosis. The trial demonstrated the feasibility and safety of conducting a large randomized trial for DIPG based on biomarker information and provided insights into tumor biology for the development of innovative therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.